Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
This study aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin in improving outcomes for patients with Barrett’s oesophagus.
A phase III unblinded trial to evaluate High-dose Esomeprazole (40 mg twice-daily) with or without aspirin (300 mg per day in the UK, 325 mg per day in Canada) and Low-dose Esomeprazole (20 mg once-daily) with or without aspirin in Patients with Barrett's esophagus of 1 cm or more
The primary composite endpoint was time to all-cause mortality, esophageal adenocarcinoma, or high-grade Dysplasia.
High-dose Esomeprazole and aspir…